Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Nanobiotix S.A. (NBTX)

3.71   0.03 (0.82%) 11-25 12:56
Open: 3.8 Pre. Close: 3.68
High: 3.8 Low: 3.71
Volume: 334 Market Cap: 129(M)

Technical analysis

as of: 2022-11-25 1:59:00 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.87     One year: 5.37
Support: Support1: 3.48    Support2: 2.89
Resistance: Resistance1: 4.17    Resistance2: 4.59
Pivot: 3.8
Moving Average: MA(5): 3.77     MA(20): 3.81
MA(100): 3.86     MA(250): 5.58
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 19.3     %D(3): 24.3
RSI: RSI(14): 45.7
52-week: High: 10.42  Low: 2.31
Average Vol(K): 3-Month: 2 (K)  10-Days: 3 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NBTX ] has closed above bottom band by 32.8%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.08 - 4.12 4.12 - 4.14
Low: 3.61 - 3.64 3.64 - 3.66
Close: 3.63 - 3.68 3.68 - 3.71

Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Headline News

Tue, 15 Nov 2022
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference - The Bakersfield Californian

Tue, 15 Nov 2022
2022-11-14 | NDAQ:NBTX | Press Release | Nanobiotix S.A. - Stockhouse

Fri, 11 Nov 2022
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript - Seeking Alpha

Wed, 09 Nov 2022
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update - Nanobiotix (NASDAQ:NBTX) - Benzinga

Wed, 02 Nov 2022
Post-traumatic Stress Disorder Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight - GlobeNewswire

Wed, 02 Nov 2022
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3 - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 35 (M)
% Held by Insiders 2.771e+007 (%)
% Held by Institutions 0 (%)
Shares Short 12 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.76e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 795.8
Return on Equity (ttm) -29.2
Qtrly Rev. Growth 2.66e+006
Gross Profit (p.s.) 0.39
Sales Per Share -96.93
EBITDA (p.s.) 1.29268e+006
Qtrly Earnings Growth -1.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -32 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 152.1

Stock Dividends

Dividend 0
Forward Dividend 1970
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.